The National Institutes of Health (NIH) raised concern about the safety of AstraZeneca’s coronavirus vaccine as the U.S. Food and Drug Administration is weighing whether or not to resume testing in the United States following a global pause in the Phase III trial for safety reasons.

The U.S. Food and Drug Administration said AstraZeneca Plc’s Covid-19 vaccine trial in the United States is still on hold, and the FDA was working with the company to figure out if there was a significant safety issue or not.

Although it’s increasingly likely that one of the Covid-19 vaccines being tested will be approved or receive Emergency Use Authorization (EUA) before the end of 2020, experts are increasingly warning that widespread distribution may take a much longer time.

AstraZeneca resumed the company’s Covid-19 vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

AstraZeneca resumed British clinical trials of the company’s Covid-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs.

Pfizer Inc and BioNTech SE proposed to the U.S Food and Drug Administration to expand their Phase 3 pivotal Covid-19 vaccine trial to about 44,000 participants while increasing the diversity of the study population.

U.S. drugmaker Merck & Co. Inc. began recruiting participants to the company’s early-stage Covid-19 vaccine study, according to the government database

AstraZeneca Plc paused global trials, including large late-stage studies, of the company’s experimental coronavirus vaccine because of an unexplained illness in a study participant.

To effectively create immunity to Covid-19, we need to educate to vaccinate.

To quell concerns over the politicization of a potential vaccine for the novel coronavirus, nine pharmaceutical companies developing a preventative treatment signed a pledge promising to uphold the integrity of the scientific process ahead of any potential approval of a medication.